158 related articles for article (PubMed ID: 34044016)
21. Periostin induces epithelial‑to‑mesenchymal transition via the integrin α5β1/TWIST‑2 axis in cholangiocarcinoma.
Sonongbua J; Siritungyong S; Thongchot S; Kamolhan T; Utispan K; Thuwajit P; Pongpaibul A; Wongkham S; Thuwajit C
Oncol Rep; 2020 Apr; 43(4):1147-1158. PubMed ID: 32020235
[TBL] [Abstract][Full Text] [Related]
22. Epithelial to mesenchymal transition is associated with shorter disease-free survival in hepatocellular carcinoma.
Yamada S; Okumura N; Wei L; Fuchs BC; Fujii T; Sugimoto H; Nomoto S; Takeda S; Tanabe KK; Kodera Y
Ann Surg Oncol; 2014 Nov; 21(12):3882-90. PubMed ID: 24833103
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-105 promotes epithelial-mesenchymal transition of nonsmall lung cancer cells through upregulating Mcl-1.
Jin X; Yu Y; Zou Q; Wang M; Cui Y; Xie J; Wang Z
J Cell Biochem; 2019 Apr; 120(4):5880-5888. PubMed ID: 30317672
[TBL] [Abstract][Full Text] [Related]
24. Long noncoding RNA SNHG7 contributes to cell proliferation, migration, invasion and epithelial to mesenchymal transition in non-small cell lung cancer by regulating miR-449a/TGIF2 axis.
Pang L; Cheng Y; Zou S; Song J
Thorac Cancer; 2020 Feb; 11(2):264-276. PubMed ID: 31793741
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-221-3p, a TWIST2 target, promotes cervical cancer metastasis by directly targeting THBS2.
Wei WF; Zhou CF; Wu XG; He LN; Wu LF; Chen XJ; Yan RM; Zhong M; Yu YH; Liang L; Wang W
Cell Death Dis; 2017 Dec; 8(12):3220. PubMed ID: 29242498
[TBL] [Abstract][Full Text] [Related]
26. Twist2 is a valuable prognostic biomarker for colorectal cancer.
Yu H; Jin GZ; Liu K; Dong H; Yu H; Duan JC; Li Z; Dong W; Cong WM; Yang JH
World J Gastroenterol; 2013 Apr; 19(15):2404-11. PubMed ID: 23613636
[TBL] [Abstract][Full Text] [Related]
27. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
[TBL] [Abstract][Full Text] [Related]
28. Thymoquinone induces cytotoxicity and reprogramming of EMT in gastric cancer cells by targeting PI3K/Akt/mTOR pathway.
Feng LM; Wang XF; Huang QX
J Biosci; 2017 Dec; 42(4):547-554. PubMed ID: 29229873
[TBL] [Abstract][Full Text] [Related]
29. Correlation of TWIST2 up-regulation and epithelial-mesenchymal transition during tumorigenesis and progression of cervical carcinoma.
Li Y; Wang W; Wang W; Yang R; Wang T; Su T; Weng D; Tao T; Li W; Ma D; Wang S
Gynecol Oncol; 2012 Jan; 124(1):112-8. PubMed ID: 22018873
[TBL] [Abstract][Full Text] [Related]
30. NANOG regulates epithelial-mesenchymal transition via AMPK/mTOR signalling pathway in ovarian cancer SKOV-3 and A2780 cells.
Yun H; Han GH; Kim J; Chung JY; Kim JH; Cho H
J Cell Mol Med; 2022 Oct; 26(20):5277-5291. PubMed ID: 36114703
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of TWIST2 correlates with poor prognosis in head and neck squamous cell carcinomas.
Gasparotto D; Polesel J; Marzotto A; Colladel R; Piccinin S; Modena P; Grizzo A; Sulfaro S; Serraino D; Barzan L; Doglioni C; Maestro R
Oncotarget; 2011 Dec; 2(12):1165-75. PubMed ID: 22201613
[TBL] [Abstract][Full Text] [Related]
32. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
Jin D; Guo J; Wu Y; Du J; Wang X; An J; Hu B; Kong L; Di W; Wang W
Theranostics; 2019; 9(7):2036-2055. PubMed ID: 31037155
[No Abstract] [Full Text] [Related]
33. Role of TWIST2, E-cadherin and Vimentin in epithelial ovarian carcinogenesis and prognosis and their interaction in cancer progression.
Li X; Yang J; Wang X; Li X; Liang J; Xing H
Eur J Gynaecol Oncol; 2016; 37(1):100-8. PubMed ID: 27048119
[TBL] [Abstract][Full Text] [Related]
34. MTA1 promotes epithelial to mesenchymal transition and metastasis in non-small-cell lung cancer.
Ma K; Fan Y; Dong X; Dong D; Guo Y; Wei X; Ning J; Geng Q; Wang C; Hu Y; Li M; Niu W; Li E; Wu Y
Oncotarget; 2017 Jun; 8(24):38825-38840. PubMed ID: 28418915
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells.
Kim EY; Kim A; Kim SK; Kim HJ; Chang J; Ahn CM; Chang YS
Respir Res; 2014 Feb; 15(1):26. PubMed ID: 24571487
[TBL] [Abstract][Full Text] [Related]
36. Potential function of oxymatrine as a novel suppressor of epithelial-to-mesenchymal transition in lung tumor cells.
Jung YY; Baek SH; Narula AS; Namjoshi OA; Blough BE; Ahn KS
Life Sci; 2021 Nov; 284():119893. PubMed ID: 34454947
[TBL] [Abstract][Full Text] [Related]
37. Effects of miR-202-5p silencing PIK3CA gene expression on proliferation, invasion, and epithelial-mesenchymal transition of cervical cancer SiHa cells through inhibiting PI3K/Akt/mTOR signaling pathway activation.
Zheng Y; Xie L; Xu S; Yan W; Zhang H; Meng Y; Liu J; Wei X
Mol Cell Biochem; 2021 Nov; 476(11):4031-4044. PubMed ID: 34244973
[TBL] [Abstract][Full Text] [Related]
38. AMP-activated protein kinase promotes epithelial-mesenchymal transition in cancer cells through Twist1 upregulation.
Saxena M; Balaji SA; Deshpande N; Ranganathan S; Pillai DM; Hindupur SK; Rangarajan A
J Cell Sci; 2018 Jul; 131(14):. PubMed ID: 29950484
[TBL] [Abstract][Full Text] [Related]
39. Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma.
Cheong CM; Mrozik KM; Hewett DR; Bell E; Panagopoulos V; Noll JE; Licht JD; Gronthos S; Zannettino ACW; Vandyke K
Cancer Lett; 2020 Apr; 475():99-108. PubMed ID: 32014459
[TBL] [Abstract][Full Text] [Related]
40. TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer.
Galván JA; Helbling M; Koelzer VH; Tschan MP; Berger MD; Hädrich M; Schnüriger B; Karamitopoulou E; Dawson H; Inderbitzin D; Lugli A; Zlobec I
Oncotarget; 2015 Jan; 6(2):874-85. PubMed ID: 25528769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
